Anumana ECG-AI
Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.
Last updated: June 5, 2026
Back to directoryFDA De Novo-authorized AI/ML software that assigns adult emergency department or hospital patients to sepsis risk categories within a clinician-reviewed workflow.
Hospitals evaluating transparent sepsis risk stratification that combines clinical data and biomarkers with EMR-integrated review for suspected sepsis workflows.
Compare within workflow: Precision medicine and data · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Prenosis Sepsis ImmunoScore as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as prescription AI/ML-based medical-device software and match use to FDA De Novo DEN230036, including suspected sepsis context, adult ED or hospital patients, blood-culture workflow, and clinician-review requirements. |
|---|---|
| Privacy | Review EHR, lab, biomarker, and cloud algorithm-suite data flows; PHI transfer; retention; access controls; security certifications; audit logs; and BAA or data-processing terms before production use. |
| Evidence | Validate local performance against sepsis prevalence, laboratory workflows, demographics, comorbidities, SEP-1 objectives, false-positive burden, and missed-sepsis risk rather than relying on authorization alone. |
| Workflow | Best governed through emergency medicine, hospital medicine, infectious disease, nursing, lab, quality, and informatics teams with clear escalation, override, monitoring, and downtime procedures. |
Prenosis describes Sepsis ImmunoScore as an FDA De Novo-authorized AI sepsis diagnostic and predictive tool that combines up to 22 patient parameters, biomarkers, vital signs, demographics, and EHR data; FDA records list DEN230036, and Roche navify materials describe cloud-based algorithm-suite deployment and intended-use boundaries.
Not for: Standalone sepsis diagnosis, use outside the FDA-authorized intended population, or replacing laboratory findings, clinical assessment, sepsis protocols, and clinician judgment.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.